Eli Lilly and Company (SWX:LLY)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 811.37B +46.8% |
| Revenue (ttm) | 57.95B +47.4% |
| Net Income | 20.28B +127.6% |
| EPS | 22.58 +129.1% |
| Shares Out | n/a |
| PE Ratio | 40.02 |
| Forward PE | 31.59 |
| Dividend | 5.07 (0.54%) |
| Ex-Dividend Date | May 15, 2026 |
| Volume | n/a |
| Open | n/a |
| Previous Close | 930.00 |
| Day's Range | n/a |
| 52-Week Range | 560.00 - 1,010.00 |
| Beta | 0.51 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial numbers in USD Financial StatementsNews
JPMorgan names 3 stocks worth buying ahead of August earnings
US stock market is entering August against a turbulent backdrop, featuring continued Iran-driven volatility in oil prices and an ongoing earnings season. Plus, investors are still processing the recen...
Eli Lilly to offer early access to next-gen obesity drug to some patients
Eli Lilly said on Monday it would allow a limited number of patients to have early access to its experimental obesity drug, retatrutide, before its U.S. FDA approval.
Eli Lilly tells Stat it will let more patients apply for retatrutide access
An Eli Lilly (LLY) spokesperson confirmed to Stat News that it will allow other patients to apply for early access to retatrutide, an unapproved obesity drug. The news comes six…
Eli Lilly Stock (LLY) Is Down Nearly 10% Heading into Earnings. Time to Buy?
The company’s Q2 results will be the first to include sales of its obesity pill.
5 Things to Know Before the Stock Market Opens on Monday
Stock futures are pointing to a higher open to kick off August trading as investors look ahead to a packed week of earnings reports; oil prices are tumbling after the U.S. paused strikes on Iran over ...
Eli Lilly says FDA grants Breakthrough Therapy designation to olomorasib
Eli Lilly (LLY) and Company announced that the U.S. FDA has granted Breakthrough Therapy designation to olomorasib as a monotherapy for the treatment of adult patients with advanced pancreatic cancer…
Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer
INDIANAPOLIS, Aug. 3, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olomorasib...
Obesity battle heats up again as Novo claws way back into race with Lilly
Novo Nordisk investors have found little cause for optimism during a bruising two-year period of profit warnings, leadership upheaval and a sliding share price as rival Eli Lilly streaked ahead. Now ...
Jobs Report, Palantir, AMD, SpaceX, Eli Lilly, and More to Watch This Week
In another heavy earnings week, we'll also see reports from McDonald's, Disney, Uber, Devon Energy, and more.
Novo Nordisk Wipes Out $30 Billion In Market Value After Failed Heart Drug Trial
$30.7 billion. That's how much was cut from Novo Nordisk's market capitalization as of Friday's share price, lowering from $229.2 billion to $198.5 billion, marking a nearly 69% decline since hitting ...
Eli Lilly (LLY) Is Investing Another $750 Million in Its U.S. Manufacturing Capacity
The company is spending a total of $55 billion on U.S. manufacturing.
Lilly, Resilience to invest $750 million in US drug manufacturing expansion
Drugmaker Eli Lilly and privately held contract manufacturer Resilience will invest $750 million to expand pharmaceutical manufacturing capacity in the U.S. and strengthen the domestic medicine supp...
These 2 stocks are worth watching amidst ongoing stock market rotation
The benchmark S&P 500 index has spent the summer coiled in a tight range just below its “short-term moving averages,” currently down over 3% from its June high. Beneath this surface-level stillness, a...
Goldman Sachs Forecasts Weak Obesity Pill Sales from Eli Lilly (LLY)
The pharma giant’s weight-loss pill was approved on April 1 of this year.
Novo Nordisk Pursues Injunction to Block Eli Lilly’s (LLY) Advertisements
The two companies dominate the market for obesity medications.
As Lilly and Novo Clash in Court, Wall Street Is Eyeing This Bigger Prize
The legal battle between Novo Nordisk and Eli Lilly is escalating, but analysts are more focused on developments in the lab.
Novo Nordisk Seeks Injunction Against Eli Lilly in Dispute Over Weight-Loss Ads
Friday's preliminary injunction request escalates legal proceedings initiated earlier this week.
Novo Nordisk seeks preliminary injunction against Lilly weight-loss ads
Novo Nordisk said on Friday it is seeking a preliminary U.S. court injunction to immediately block obesity and diabetes drug advertisements by Eli Lilly , in a further escalation of the rivalry bet...
Lilly's Next-Generation Obesity Shot Clears Another Hurdle
Eli Lilly & Co.'s next-generation weight-loss shot retatrutide didn't increase overall heart risk in a new study, helping dispel concerns over its potential. The company plans to file for US Food and ...
Eli Lilly (LLY) Targets 2027 for Approval of Its Next-Generation Obesity Drug
The new medication helps people who also have diabetes and cardiovascular disease.
Eli Lilly Will File For Retatrutide Approval—As Study Shows Average Weight Loss Of 56 Pounds
Analysts have suggested retatrutide could become a blockbuster weight loss drug if approved. In January, TD Cowen analysts estimated retatrutide could generate $3.8 billion in sales in 2030, while Glo...
Eli Lilly notes retatrutide met primary endpoint in TRIUMPH-2, TRIUMPH-3 trials
Eli Lilly (LLY) announced topline results from TRIUMPH-2 and TRIUMPH-3, two Phase 3 trials evaluating retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor a...
Eli Lilly Preparing Retatrutide Applications After Positive Weight-Loss Data
Eli Lilly is preparing application materials for its next-generation weight-loss drug, retatrutide, following data from two Phase 3 trials showing the treatment delivered substantial results.
Lilly announces more next-gen obesity drug data, plans Q1 2027 FDA application
Eli Lilly on Thursday said two more Phase 3 trials of its experimental obesity drug retatrutide showed positive results and it plans to submit an application to the U.S. Food and Drug Administration ...
Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials
Eli Lilly said it will file for approval of its next-generation obesity drug, retatrutide, in the first quarter of 2027, as it succeeds in two more late-stage trials. The drug delivered significant w...